Bloch Stephen M sold $14.0M of LQDA (indirect holdings)

Bloch Stephen M sold 196,111 indirectly-held shares of Liquidia Corp (LQDA) at an average of $71.45 ($71.37–$72.15, $14.01M total) across 4 trades over 2026-06-12 to 2026-06-15.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 16, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The newest information is the disclosed $14.0M open-market sale (196,111 shares) and the director’s post-transaction holdings (980,073 shares), with no 10b5-1 plan cited.

02

Market read

Traders may react to the disclosed insider selling size and the absence of a 10b5-1 plan, but there is no accompanying operational or financial update.

03

What to watch

The filing states the sales were not under a pre-arranged 10b5-1 plan, but it does not disclose the director’s broader compensation/financial needs or whether other holdings were adjusted concurrently.

Relevance 7/10Novelty 8/10Timing: Filed 2026-06-16; sale executed 2026-06-12 to 2026-06-15.

Background

This is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia director Stephen M. Bloch sold $14.0M of LQDA shares via open-market transactions (Form 4) during 2026-06-12 to 2026-06-15.

Expected impact

Near-term: slight bearish bias; magnitude likely limited because it’s a disclosed Form 4 without new fundamentals.

Evidence & confidence

The article provides a concrete sale size, timing, and role (director) plus absence of a pre-arranged 10b5-1 plan, which traders may interpret as higher signaling risk.

Market effects

Limited sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity management and may not reflect company outlook, especially when multiple small trades are spread across days.

Key entities

  • Liquidia Corp

    US-listed company whose director insider sale is disclosed on Form 4.

  • Stephen M. Bloch

    Director reporting the open-market sale of LQDA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.